Patient-derived organoids (PDOs) from EUS-guided biopsies show high success rate in establishing models for pancreatic ductal adenocarcinoma (PDAC). PDAC PDOs accurately reflect genetic alterations in the original tumors and predict drug sensitivity, including resistance to nab-paclitaxel. This innovative model enables rapid testing of multiple therapeutic drugs, offering a personalized “patient avatar” for timely clinical decision-making in PDAC treatment.
Video-Audio Media by Kim H, Jang J (…) Park JK et 16 al. in Gastrointest Endosc
Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.